FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225014135> ?p ?o ?g. }

• W4225014135 endingPage "S3" @default.
• W4225014135 startingPage "S3" @default.
• W4225014135 abstract "Introduction Sodium-glucose co-transporter 2 inhibitors (SGLT2i) reduce hospitalization and mortality in chronic heart failure and kidney disease, and are actively being tested in acute settings. Recent pre-clinical studies suggest that SGLT2i improve survival and renal inflammation acutely after lipopolysaccharide (LPS) administration, but just as in the chronic setting, the downstream beneficial effects of SGLT2i remain elusive. In response to cardiometabolic disease or inflammation, humans and mice downregulate the apolipoprotein M (ApoM) / sphingosine-1-phosphate (S1P) pathway, leading to increased death and organ injury. Because of the phenotypic similarities between SGLT2 inhibition and the ApoM/S1P pathway, we hypothesized that the SGLT2i dapagliflozin (Dapa) improves cardiorenal outcomes in a murine LPS model via an ApoM/S1P dependent pathway. Methods Diet-induced obesity mice were randomized to Dapa (1 mg/kg PO) or vehicle for 4 days, followed by saline or LPS (10 mg/kg IP), echocardiography, and euthanasia. To assess if Dapa attenuates vascular permeability and neutrophil transendothelial migration, intravital microscopy (IVM) was performed in chow-fed Ly6g-cre Tdtomato mice, ApoM transgenic (ApomTG) mice, and littermate controls. Results Dapa attenuated LPS-induced reductions in cardiac index (-3% with Dapa vs -48% in controls, p<0.01), end-diastolic volume index (+28% with Dapa vs -34% in controls, p<0.01), coronary sinus area (+27% with Dapa vs -75% in controls, p<0.05), and serum ApoM (-5% with Dapa vs -60% in controls, p<0.01). IVM demonstrated that Dapa reduced vascular leak and neutrophil transendothelial migration. ApomTG mice demonstrated reduced vascular leak, but were insensitive to Dapa, while treatment of mice with an S1P receptor inhibitor blocked the effects of Dapa on vascular leak. Conclusions The effects of SGLT2i on endothelial integrity and cardiac function are clinically relevant to conditions such as sepsis and heart failure, among others, and merit further clinical investigation. ApoM/S1P signaling is a critical downstream link that mediates the beneficial effects of Dapa on endothelial barrier integrity. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) reduce hospitalization and mortality in chronic heart failure and kidney disease, and are actively being tested in acute settings. Recent pre-clinical studies suggest that SGLT2i improve survival and renal inflammation acutely after lipopolysaccharide (LPS) administration, but just as in the chronic setting, the downstream beneficial effects of SGLT2i remain elusive. In response to cardiometabolic disease or inflammation, humans and mice downregulate the apolipoprotein M (ApoM) / sphingosine-1-phosphate (S1P) pathway, leading to increased death and organ injury. Because of the phenotypic similarities between SGLT2 inhibition and the ApoM/S1P pathway, we hypothesized that the SGLT2i dapagliflozin (Dapa) improves cardiorenal outcomes in a murine LPS model via an ApoM/S1P dependent pathway. Diet-induced obesity mice were randomized to Dapa (1 mg/kg PO) or vehicle for 4 days, followed by saline or LPS (10 mg/kg IP), echocardiography, and euthanasia. To assess if Dapa attenuates vascular permeability and neutrophil transendothelial migration, intravital microscopy (IVM) was performed in chow-fed Ly6g-cre Tdtomato mice, ApoM transgenic (ApomTG) mice, and littermate controls. Dapa attenuated LPS-induced reductions in cardiac index (-3% with Dapa vs -48% in controls, p<0.01), end-diastolic volume index (+28% with Dapa vs -34% in controls, p<0.01), coronary sinus area (+27% with Dapa vs -75% in controls, p<0.05), and serum ApoM (-5% with Dapa vs -60% in controls, p<0.01). IVM demonstrated that Dapa reduced vascular leak and neutrophil transendothelial migration. ApomTG mice demonstrated reduced vascular leak, but were insensitive to Dapa, while treatment of mice with an S1P receptor inhibitor blocked the effects of Dapa on vascular leak. The effects of SGLT2i on endothelial integrity and cardiac function are clinically relevant to conditions such as sepsis and heart failure, among others, and merit further clinical investigation. ApoM/S1P signaling is a critical downstream link that mediates the beneficial effects of Dapa on endothelial barrier integrity." @default.
• W4225014135 created "2022-04-29" @default.
• W4225014135 creator A5001500424 @default.
• W4225014135 creator A5007479997 @default.
• W4225014135 creator A5008074315 @default.
• W4225014135 creator A5008210851 @default.
• W4225014135 creator A5008394739 @default.
• W4225014135 creator A5021833046 @default.
• W4225014135 creator A5021946878 @default.
• W4225014135 creator A5036567739 @default.
• W4225014135 creator A5047089667 @default.
• W4225014135 creator A5052533254 @default.
• W4225014135 creator A5055598414 @default.
• W4225014135 creator A5081714923 @default.
• W4225014135 creator A5086636722 @default.
• W4225014135 date "2022-04-01" @default.
• W4225014135 modified "2023-10-18" @default.
• W4225014135 title "Dapagliflozin Improves Endothelial Integrity And Cardiac Loading Through A Sphingosine-1-phosphate / Apolipoprotein M Dependent Pathway" @default.
• W4225014135 doi "https://doi.org/10.1016/j.cardfail.2022.03.010" @default.
• W4225014135 hasPublicationYear "2022" @default.
• W4225014135 type Work @default.
• W4225014135 citedByCount "1" @default.
• W4225014135 countsByYear W42250141352023 @default.
• W4225014135 crossrefType "journal-article" @default.
• W4225014135 hasAuthorship W4225014135A5001500424 @default.
• W4225014135 hasAuthorship W4225014135A5007479997 @default.
• W4225014135 hasAuthorship W4225014135A5008074315 @default.
• W4225014135 hasAuthorship W4225014135A5008210851 @default.
• W4225014135 hasAuthorship W4225014135A5008394739 @default.
• W4225014135 hasAuthorship W4225014135A5021833046 @default.
• W4225014135 hasAuthorship W4225014135A5021946878 @default.
• W4225014135 hasAuthorship W4225014135A5036567739 @default.
• W4225014135 hasAuthorship W4225014135A5047089667 @default.
• W4225014135 hasAuthorship W4225014135A5052533254 @default.
• W4225014135 hasAuthorship W4225014135A5055598414 @default.
• W4225014135 hasAuthorship W4225014135A5081714923 @default.
• W4225014135 hasAuthorship W4225014135A5086636722 @default.
• W4225014135 hasConcept C126322002 @default.
• W4225014135 hasConcept C134018914 @default.
• W4225014135 hasConcept C170493617 @default.
• W4225014135 hasConcept C2776596873 @default.
• W4225014135 hasConcept C2776914184 @default.
• W4225014135 hasConcept C2777180221 @default.
• W4225014135 hasConcept C2777422806 @default.
• W4225014135 hasConcept C2778198053 @default.
• W4225014135 hasConcept C2778653478 @default.
• W4225014135 hasConcept C2778703144 @default.
• W4225014135 hasConcept C2778754761 @default.
• W4225014135 hasConcept C2779676291 @default.
• W4225014135 hasConcept C541997718 @default.
• W4225014135 hasConcept C555293320 @default.
• W4225014135 hasConcept C71924100 @default.
• W4225014135 hasConcept C98274493 @default.
• W4225014135 hasConceptScore W4225014135C126322002 @default.
• W4225014135 hasConceptScore W4225014135C134018914 @default.
• W4225014135 hasConceptScore W4225014135C170493617 @default.
• W4225014135 hasConceptScore W4225014135C2776596873 @default.
• W4225014135 hasConceptScore W4225014135C2776914184 @default.
• W4225014135 hasConceptScore W4225014135C2777180221 @default.
• W4225014135 hasConceptScore W4225014135C2777422806 @default.
• W4225014135 hasConceptScore W4225014135C2778198053 @default.
• W4225014135 hasConceptScore W4225014135C2778653478 @default.
• W4225014135 hasConceptScore W4225014135C2778703144 @default.
• W4225014135 hasConceptScore W4225014135C2778754761 @default.
• W4225014135 hasConceptScore W4225014135C2779676291 @default.
• W4225014135 hasConceptScore W4225014135C541997718 @default.
• W4225014135 hasConceptScore W4225014135C555293320 @default.
• W4225014135 hasConceptScore W4225014135C71924100 @default.
• W4225014135 hasConceptScore W4225014135C98274493 @default.
• W4225014135 hasIssue "5" @default.
• W4225014135 hasLocation W42250141351 @default.
• W4225014135 hasOpenAccess W4225014135 @default.
• W4225014135 hasPrimaryLocation W42250141351 @default.
• W4225014135 hasRelatedWork W2096284471 @default.
• W4225014135 hasRelatedWork W2113751484 @default.
• W4225014135 hasRelatedWork W2136518857 @default.
• W4225014135 hasRelatedWork W2138608795 @default.
• W4225014135 hasRelatedWork W2145943006 @default.
• W4225014135 hasRelatedWork W2148711924 @default.
• W4225014135 hasRelatedWork W2153962342 @default.
• W4225014135 hasRelatedWork W2748952813 @default.
• W4225014135 hasRelatedWork W3007081498 @default.
• W4225014135 hasRelatedWork W3020836689 @default.
• W4225014135 hasVolume "28" @default.
• W4225014135 isParatext "false" @default.
• W4225014135 isRetracted "false" @default.
• W4225014135 workType "article" @default.